This is therefore a contrasting of the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation in Bio-Rad Laboratories Inc. (NYSE:BIO.B) and Organovo Holdings Inc. (NASDAQ:ONVO). The two are both Medical Laboratories & Research companies that compete with one another.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bio-Rad Laboratories Inc.||298||4.14||N/A||19.00||17.05|
|Organovo Holdings Inc.||1||11.46||N/A||-0.23||0.00|
In table 1 we can see Bio-Rad Laboratories Inc. and Organovo Holdings Inc.’s gross revenue, earnings per share and valuation.
Table 2 provides us the return on assets, net margins and return on equity of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Bio-Rad Laboratories Inc.||0.00%||0%||0%|
|Organovo Holdings Inc.||0.00%||-70%||-63.4%|
Insider & Institutional Ownership
Institutional investors owned 0% of Bio-Rad Laboratories Inc. shares and 38.5% of Organovo Holdings Inc. shares. Insiders Comparatively, owned 0.7% of Organovo Holdings Inc. shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Bio-Rad Laboratories Inc.||4%||18.68%||9.82%||83.56%||170.61%||40.86%|
|Organovo Holdings Inc.||-7.41%||-16.45%||-59.08%||-59.48%||-64.68%||-56.82%|
For the past year Bio-Rad Laboratories Inc. had bullish trend while Organovo Holdings Inc. had bearish trend.
Bio-Rad Laboratories Inc. beats Organovo Holdings Inc. on 6 of the 8 factors.
Organovo Holdings, Inc., an early commercial stage company, designs and creates functional and three-dimensional (3D) human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. Its 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company offers two commercial products, which include ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing a suite of standardized and 3D human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology, or disease for use in drug discovery and development, and disease modeling; and 3D human tissues for clinical applications, such as therapeutic liver tissue patch. Organovo Holdings, Inc. was founded in 2007 and is headquartered in San Diego, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.